An update on the pharmacotherapy of osteoporosis.
Level 5 - mechanism / opinion, no new human data
Narrative review of guidelines and pharmacotherapy without systematic review methodology
PubMed 40178951 · doi:10.1080/14656566.2025.2489122
What was done
Synthesized recent literature and guidelines from international societies to summarize current diagnostic practices, pharmacotherapy options, and management strategies for osteoporosis.
What was found
The abstract reports no numerical findings. It notes that bisphosphonates serve as cost-effective first-line therapy, denosumab and anabolic agents (teriparatide, romosozumab) are alternatives for high-risk patients, and bone mineral density assessments are needed to address underdiagnosis, particularly in men.
Why it matters
Summarizes contemporary clinical guideline recommendations for risk-stratified pharmacotherapy and prevention of fragility fractures.
Limits
Narrative review design with no systematic search protocol, quality assessment, or quantitative pooling. The abstract provides no primary data, sample sizes, or statistical comparisons.
Cited by
- supports Bisphosphonates are considered first-line pharmacological therapy for osteoporosis.